Eli Lilly (LLY) said Sunday that its weight-loss drug showed results superior to Novo Nordisk's (NVO) Wegovy in a phase 3 study evaluating the safety and efficacy of the two drugs over 72 weeks in obese or overweight patients with at least one weight-related medical problem and without diabetes.

The company asid Zepbound met its primary endpoint of weight loss, reducing weight by 20.2% or 50.3 pounds compared to 13.7% or 33.1 pounds for Wegovy.

The drug also met all five of its secondary endpoints in the study, the company said.